[Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
D001593:Benzyl Compounds / Q000627:therapeutic use*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D012701:Serotonin / Q000378:metabolism
D001593:Benzyl Compounds; D004338:Drug Combinations; D006834:Hydrazines; D012701:Serotonin; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
Syndrome de Parkinson. Quatre ans d'expérience de la théraopeutique par la L-Dopa associée à un inhibiteur de la décarboxylase. Etude clinique et biochimique.